Your account is not claimed yet. You can sign up with ORCID to claim your account.

Yurong Lai

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2016-2023
Publications (10 Years): 34

Top Venues

Drug metabolism and disposition: the biological fate of chemicals

CPT: pharmacometrics & systems pharmacology

Clinical pharmacology and therapeutics

Xenobiotica; the fate of foreign compounds in biological systems

Gilead Sciences Inc

Sapporo Ika Daigaku (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Gilead Sciences Inc Feb 1o 2017

United States

Senior Director :: Metabolism

Education History

Sapporo Ika Daigaku Jul 6o 1994 - Apr 1o 1998

Japan

PHD :: Toxicology

Publications

Raju Subramanian, John Ling, Jianhong Wang, Kelly Wang, Jia Hao, Haolun Jin, Yurong Lai, Bernard Murray, Samantha Wijaya, Heather Zhang, Bill J Smith
Human and nonclinical disposition of [ 14 C]bictegravir, a potent integrase strand-transfer inhibitor for the treatment of HIV-1 infection. Xenobiotica; the fate of foreign compounds in biological systems (2023)
Yurong Lai, Xiao-Bo Zhong
Special Section on Mechanism-Based Predictive Methods in Drug Discovery and Development-Editorial. Drug metabolism and disposition: the biological fate of chemicals 51 (9) (2023)
Raju Subramanian, John Ling, Jianhong Wang, Kelly Wang, Jia Hao, Haolun Jin, Yurong Lai, Bernard Murray, Samantha Wijaya, Heather Zhang, Bill J Smith
Human and nonclinical disposition of [ 14 C]bictegravir, a potent integrase strand-transfer inhibitor for the treatment of HIV-1 infection. Xenobiotica; the fate of foreign compounds in biological systems 52 (9-11) (2023)
Yurong Lai, Xinxin Ding
Special Section on Perspectives on Drug Metabolism and Disposition, Part I-Editorial. Drug metabolism and disposition: the biological fate of chemicals 51 (6) (2023)
Yurong Lai
The Role of Coproporphyrins as Endogenous Biomarkers for Organic Anion Transporting Polypeptide 1B Inhibition - progress from 2016 to 2023 . Drug metabolism and disposition: the biological fate of chemicals (2023)
Xiao-Bo Zhong, Yurong Lai, Xinxin Ding
Special Section on New and Emerging Areas and Technologies in Drug Metabolism and Disposition, Part I-Editorial. Drug metabolism and disposition: the biological fate of chemicals 51 (10) (2023)
Mengyue Yin, Kazuya Ishida, Xiaomin Liang, Yurong Lai, Jashvant D Unadkat
Interpretation of Protein-Mediated Uptake of Statins by Hepatocytes is Confounded by the R esidua l Statin-Protein Complex . Drug metabolism and disposition: the biological fate of chemicals (2023)
Yurong Lai, Xinxin Ding
Special Section on Perspectives on Drug Metabolism and Disposition, Part I-Editorial. Drug metabolism and disposition: the biological fate of chemicals 51 (6) (2023)
Renmeng Liu, Jia Hao, Xiaofeng Zhao, Yurong Lai
Characterization of Elimination Pathways and the Feasibility of Endogenous Metabolites as Biomarkers of Organic Anion Transporter 1/3 (Oat1/3) Inhibition in Cynomolgus Monkeys . Drug metabolism and disposition: the biological fate of chemicals (2023)
Xiao-Bo Zhong, Yurong Lai
Special Section on Drug Metabolism and Precision Medicine-Editorial. Drug metabolism and disposition: the biological fate of chemicals 51 (3) (2023)
Raju Subramanian, John Ling, Jianhong Wang, Kelly Wang, Jia Hao, Haolun Jin, Yurong Lai, Bernard Murray, Samantha Wijaya, Heather Zhang, Bill J Smith
Human and nonclinical disposition of [ 14 C]bictegravir, a potent integrase strand-transfer inhibitor for the treatment of HIV-1 infection. Xenobiotica; the fate of foreign compounds in biological systems 52 (9-11) (2023)
Xiao-Bo Zhong, Yurong Lai
Special Section on Drug Metabolism and Precision Medicine-Editorial. Drug metabolism and disposition: the biological fate of chemicals 51 (3) (2023)
Flavia Storelli, Mayur K Ladumor, Xiaomin Liang, Yurong Lai, Paresh P Chothe, Osatohanmwen J Enogieru, Raymond Evers, Jashvant D Unadkat
Towards improved predictions of pharmacokinetics of transported drugs in hepatic impairment: insights from the extended clearance model. CPT: pharmacometrics & systems pharmacology (2023)
Mayur K Ladumor, Flavia Storelli, Xiaomin Liang, Yurong Lai, Osatohanmwen J Enogieru, Paresh P Chothe, Raymond Evers, Jashvant D Unadkat
Predicting changes in the pharmacokinetics of CYP3A-metabolized drugs in hepatic impairment and insights into factors driving these changes. CPT: pharmacometrics & systems pharmacology 12 (2) (2022)
Mayur K Ladumor, Flavia Storelli, Xiaomin Liang, Yurong Lai, Osatohanmwen J Enogieru, Paresh P Chothe, Raymond Evers, Jashvant D Unadkat
Predicting changes in the pharmacokinetics of CYP3A-metabolized drugs in hepatic impairment and insights into factors driving these changes. CPT: pharmacometrics & systems pharmacology 12 (2) (2022)
Mayur K Ladumor, Flavia Storelli, Xiaomin Liang, Yurong Lai, Osatohanmwen J Enogieru, Paresh P Chothe, Raymond Evers, Jashvant D Unadkat
Predicting changes in the pharmacokinetics of CYP3A-metabolized drugs in hepatic impairment and insights into factors driving these changes. CPT: pharmacometrics & systems pharmacology (2022)
Kunal S Taskar, Xinning Yang, Sibylle Neuhoff, Mitesh Patel, Kenta Yoshida, Mary F Paine, Kim L R Brouwer, Xiaoyan Chu, Yuichi Sugiyama, Jack Cook, Joseph W Polli, Imad Hanna, Yurong Lai, Maciej Zamek-Gliszczynski, null null
Clinical Relevance of Hepatic and Renal P-gp/BCRP Inhibition of Drugs: An International Transporter Consortium Perspective. Clinical pharmacology and therapeutics 112 (3) (2022)
Tatsuki Mochizuki, Yasunori Aoki, Takashi Yoshikado, Kenta Yoshida, Yurong Lai, Hideki Hirabayashi, Yoshiyuki Yamaura, Kevin Rockich, Kunal Taskar, Tadayuki Takashima, Xiaoyan Chu, Maciej J Zamek-Gliszczynski, Jialin Mao, Kazuya Maeda, Kenichi Furihata, Yuichi Sugiyama, Hiroyuki Kusuhara
Physiologically-based pharmacokinetic model-based translation of OATP1B-mediated drug-drug interactions from coproporphyrin I to probe drugs. Clinical and translational science 15 (6) (2022)
Mayur K Ladumor, Flavia Storelli, Xiaomin Liang, Yurong Lai, Osatohanmwen J Enogieru, Paresh P Chothe, Raymond Evers, Jashvant D Unadkat
Predicting changes in the pharmacokinetics of CYP3A-metabolized drugs in hepatic impairment and insights into factors driving these changes. CPT: pharmacometrics & systems pharmacology 12 (2) (2022)
Raju Subramanian, John Ling, Jianhong Wang, Kelly Wang, Jia Hao, Haolun Jin, Yurong Lai, Bernard Murray, Samantha Wijaya, Heather Zhang, Bill J Smith
Human and Nonclinical Disposition of [ 14 C]Bictegravir, a Potent Integrase Strand-Transfer Inhibitor for the Treatment of HIV-1 Infection. Xenobiotica; the fate of foreign compounds in biological systems (2022)
Yurong Lai, Xiao-Bo Zhong
Special Section on Pharmacokinetics and ADME of Biological Therapeutics-Editorial. Drug metabolism and disposition: the biological fate of chemicals 50 (6) (2022)
Donglu Zhang, Cong Wei, Cornelis E C A Hop, Matthew R Wright, Ming Hu, Yurong Lai, S Cyrus Khojasteh, W Griff Humphreys
Intestinal Excretion, Intestinal Recirculation, and Renal Tubule Reabsorption Are Underappreciated Mechanisms That Drive the Distribution and Pharmacokinetic Behavior of Small Molecule Drugs. Journal of medicinal chemistry 64 (11) (2021)
Donglu Zhang, Cong Wei, Cornelis E C A Hop, Matthew R Wright, Ming Hu, Yurong Lai, S Cyrus Khojasteh, W Griff Humphreys
Correction to "Intestinal Excretion, Intestinal Recirculation, and Renal Tubule Reabsorption Are Underappreciated Mechanisms That Drive the Distribution and Pharmacokinetic Behavior of Small Molecule Drugs". Journal of medicinal chemistry 64 (21) (2021)
Xiaomin Liang, Yurong Lai
Overcoming the shortcomings of the extended-clearance concept: a framework for developing a physiologically-based pharmacokinetic (PBPK) model to select drug candidates involving transporter-mediated clearance. Expert opinion on drug metabolism & toxicology 17 (8) (2021)
Vineet Kumar, Mengyue Yin, Kazuya Ishida, Laurent Salphati, Cornelis E C A Hop, Christopher Rowbottom, Guangqing Xiao, Yurong Lai, Anita Mathias, Xiaoyan Chu, W Griffith Humphreys, Mingxiang Liao, Zsuzsanna Nerada, Nóra Szilvásy, Scott Heyward, Jashvant D Unadkat
Prediction of Transporter-Mediated Rosuvastatin Hepatic Uptake Clearance and Drug Interaction in Humans Using Proteomics-Informed REF Approach. Drug metabolism and disposition: the biological fate of chemicals 49 (2) (2020)
Xiaomin Liang, Yeojin Park, Natalie DeForest, Jia Hao, Xiaofeng Zhao, Congrong Niu, Kelly Wang, Bill Smith, Yurong Lai
In Vitro Hepatic Uptake in Human and Monkey Hepatocytes in the Presence and Absence of Serum Protein and Its In Vitro to In Vivo Extrapolation. Drug metabolism and disposition: the biological fate of chemicals 48 (12) (2020)
Maciej J Zamek-Gliszczynski, Mitesh Patel, Xinning Yang, Justin D Lutz, Xiaoyan Chu, Kim L R Brouwer, Yurong Lai, Caroline A Lee, Sibylle Neuhoff, Mary F Paine, Yuichi Sugiyama, Kunal S Taskar, Aleksandra Galetin
Intestinal P-gp and Putative Hepatic OATP1B Induction: International Transporter Consortium Perspective on Drug Development Implications. Clinical pharmacology and therapeutics 109 (1) (2020)
Congrong Niu, Yujin Wang, Xiaofeng Zhao, Sam Tep, Eisuke Murakami, Raju Subramanian, Bill Smith, Yurong Lai
Organic Anion-Transporting Polypeptide Genes Are Not Induced by the Pregnane X Receptor Activator Rifampin: Studies in Hepatocytes In Vitro and in Monkeys In Vivo. Drug metabolism and disposition: the biological fate of chemicals 47 (12) (2019)
A David Rodrigues, Yurong Lai, Hong Shen, Manthena V S Varma, Andrew Rowland, Stefan Oswald
Induction of Human Intestinal and Hepatic Organic Anion Transporting Polypeptides: Where Is the Evidence for Its Relevance in Drug-Drug Interactions? Drug metabolism and disposition: the biological fate of chemicals 48 (3) (2019)
Xiaoyan Chu, Mingxiang Liao, Hong Shen, Kenta Yoshida, Arik A Zur, Vikram Arya, Aleksandra Galetin, Kathleen M Giacomini, Imad Hanna, Hiroyuki Kusuhara, Yurong Lai, David Rodrigues, Yuichi Sugiyama, Maciej J Zamek-Gliszczynski, Lei Zhang, null null
Clinical Probes and Endogenous Biomarkers as Substrates for Transporter Drug-Drug Interaction Evaluation: Perspectives From the International Transporter Consortium. Clinical pharmacology and therapeutics 104 (5) (2019)
Sarah Billington, Laurent Salphati, Cornelis E C A Hop, Xiaoyan Chu, Raymond Evers, Doug Burdette, Christopher Rowbottom, Yurong Lai, Guangqing Xiao, W Griffith Humphreys, Tot Bui Nguyen, Bhagwat Prasad, Jashvant D Unadkat
Interindividual and Regional Variability in Drug Transporter Abundance at the Human Blood-Brain Barrier Measured by Quantitative Targeted Proteomics. Clinical pharmacology and therapeutics 106 (1) (2019)
Sarah Billington, Steven Shoner, Scott Lee, Kindra Clark-Snustad, Matthew Pennington, David Lewis, Mark Muzi, Shirley Rene, Jean Lee, Tot Bui Nguyen, Vineet Kumar, Kazuya Ishida, Laigao Chen, Xiaoyan Chu, Yurong Lai, Laurent Salphati, Cornelis E C A Hop, Guangqing Xiao, Mingxiang Liao, Jashvant D Unadkat
Positron Emission Tomography Imaging of [11 C]Rosuvastatin Hepatic Concentrations and Hepatobiliary Transport in Humans in the Absence and Presence of Cyclosporin A. Clinical pharmacology and therapeutics 106 (5) (2019)
Bridget L Morse, Jamus G MacGuire, Anthony M Marino, Yue Zhao, Maxine Fox, Yueping Zhang, Hong Shen, W Griffith Humphreys, Punit Marathe, Yurong Lai
Physiologically Based Pharmacokinetic Modeling of Transporter-Mediated Hepatic Clearance and Liver Partitioning of OATP and OCT Substrates in Cynomolgus Monkeys. The AAPS journal 19 (6) (2017)
Hong Shen, Yurong Lai, A David Rodrigues
Organic Anion Transporter 2: An Enigmatic Human Solute Carrier. Drug metabolism and disposition: the biological fate of chemicals 45 (2) (2016)

Yurong Lai.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Yurong Lai